Lord O’Neill Blames Governments And Pharma For Faltering AMR Progress
O'Neill assessed the antibiotic 'State Of Play' in a Chatham House AMR progress report
Executive Summary
Three years after completion of his high-profile AMR Review, Jim O’Neill warns that global progress on antimicrobial resistance has slowed dangerously.
You may also be interested in...
UK, Sweden Test Differing Antibiotic Market Models
Sweden and the UK are conducting differing ‘develop and test’ programs to assess so-called ‘pull’ incentives in which an antibiotics innovator will be paid an annual fee in return for an access guarantee for anti-infectives. The projects have drawn keen attention from other countries.
UK’s O’Neill ‘Frustrated’ By G20’s ‘Paltry’ AMR Message
Jim O’Neill, the British economist who helped put the dangers of antimicrobial resistance firmly on the world stage, says he’s “frustrated” by the G20’s lack of focus on AMR during its Japan summit.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.